2018台灣生技月 Bio Taiwan 生物科技大展

2018 台灣生技月 南港展覽館

PROGRAM

Witness the Unlimited Potential of Taiwan-Japan Biotech Collaboration

Time2017/06/30 (Friday) 9:00-12:00
VenueRm 504a, Taipei Nangang Exhibition Center
OrganizerDCI Partners (Daiwa Corporate Investment), Taiwan Bio Industry Organization
Co-organizerDevelopment Center for Biotechnology (DCB), Taiwan-Japan Industry Center (TJIC
Language : English

In the current global wave of biotech industry development, Taiwan and Japan are both active participants with strong incentives and robust infrastructure. As the world's third largest market for biomedicine, a mature value chain has been established in Japan with both strong pharmaceutical companies and advanced basic research providers. Taiwan, with strong entrepreneurship, an active capital market, internationalized talent, and a centralized and highly regarded healthcare system, biotechnology is building up to become one of Taiwan's most significant industries. Utilizing the complementary advantages and unlimited collaboration potential between the booming biotech industries of Taiwan and Japan, DCI Partners, a subsidiary of Daiwa Corporate Investment (DCI Group), established the "Daiwa TW-JP Biotech Fund" in 2015. Through this fund, DCI Partners is now dedicated to investing in private companies with advanced projects or platforms. Through these investments, DCI Partners aims to actively add value to the investee and facilitate increased collaboration between Taiwan and Japan.
To energize such collaboration, DCI Group is honored to organize the "Witness the Unlimited Potential of Taiwan-Japan Biotech Collaboration" forum during BioTaiwan 2017, the biggest event of the Taiwan biotech industry calendar. This forum will focus on the following topics:

  • Experience from investment and value-adding activities from DCI Group, and its observation of the industry.
  • Considerations, business models, and key factors to achieving a successful deal while increasing enterprise value, shared by companies or organizations with stories of successful Taiwan-Japan collaboration.
  • Strategic considerations for project or business development in Japan.
With different perspectives presented and discussed at this forum, DCI Partners looks forward to realizing the huge potential and benefits from Taiwan-Japan biotech collaborations. Your participation in this event will be greatly appreciated. 


 
Time Topic Speaker
08:50-09:00 Registration  
09:00-09:10 Welcome Remark DCI Partners
Hiroki Narita, CEO
09:10-09:30 Opening Remark Taiwan Bio Industry Organization
Dr. Johnsee Lee, chairman
Office of Science & Technology Executive Yuan
Stone Shih-Torng Ding, Deputy Executive Secretary
Government Officer (inviting)
09:30-09:50 Creation and management of biotech investment opportunities between Taiwan and Japan DCI Partners
Shuntaro Kodama, Managing Director
09:50-10:10 Opportunities of biotech industry in Taiwan and Japan – a perspective from International Society for Cellular therapy International Society for Cellular Therapy (ISCT)
Dr. Oscar Kuang-Sheng Lee, VP, Asia Region
10:10-10:30 Strategic Partnership for Japan/Taiwan in Regenerative Medicine, Steminent out-licensing as a case study Steminent Biotherapeutics
Ryan Chang, President
10:30-10:40 Break  
10:40-11:20 Integration of Resources in Taiwan and Japan to build up new business in CNS field National Institutes for Quantum and Radiological Science and Technology (QST)
Dr. Makoto Higuchi, Team Leader


APRINOIA Therapeutics
Dr. Ming-Kuei Jang, CEO


(Moderator)
DCI  Brian Po-Hui Chen, Director 
 
11:20-11:50 Strategy of Project/business Development in Japan Linical Taiwan
Vivian SF Lee, President & CEO
11:50 Closing Remark and Networking